Marinho, M.D., Ph.D., Fred Poordad, M.D.D., Mark S. Sulkowski, M.D., Heiner Wedemeyer, M.D., Edward Tam, M.D., Paul Desmond, M.D., Donald M. Jensen, M.D., Adrian M. Di Bisceglie, M.D., Peter Varunok, M.D., Tarek Hassanein, M.D., Junyuan Xiong, M.S., Tami Pilot-Matias, Ph.D., Barbara DaSilva-Tillmann, M.D., Lois Larsen, Ph.D., Thomas Podsadecki, M.D., and Barry Bernstein, M.D. HCV infection can be healed with antiviral therapy, reducing the risk of death and disease connected with end-stage liver disease.A 45 %increase in pathology test orders in the last 10 years partly reflects the raising management of chronic conditions. ‘Many patients on medication for chronic diseases have to be monitored regularly,’ she stated. General practice activity in Australia 2007-08 describes general practice activity based on an example of 95,300 patient encounters with 953 selected GPs. General practice activity in Australia 1998-99 to 2007-08: 10 year data tables, highlights adjustments over the last 10 years in GP workload and demand.
ANAVEX 2-73 named 2010’s ‘most promising trial drug’ by Alzheimer’s Weekly Anavex Lifestyle Sciences Corp. announced today that ANAVEX 2-73 has been named 2010’s most promising trial medication by the editorial personnel in Alzheimer’s Weekly.